KIR+ CD8+ T Lymphocytes in Cancer Immunosurveillance and Patient Survival: Gene Expression Profiling
Authors:
- Lourdes GimenoLourdes Gimeno
- Emilio M. Serrano-LópezESEmilio M. Serrano-López
- José A. CampilloJCJosé A. Campillo
- María A. Cánovas-ZapataMCMaría A. Cánovas-Zapata
- Omar S. AcuñaOmar S. Acuña
- Francisco García-CózarFrancisco García-Cózar
- María V. Martínez-SánchezMMMaría V. Martínez-Sánchez
- María D. Martínez-HernándezMMMaría D. Martínez-Hernández
- María F. Soto-RamírezMSMaría F. Soto-Ramírez
- Pedro López-CubillanaPLPedro López-Cubillana
- Jorge Martínez-EscribanoJMJorge Martínez-Escribano
- Jerónimo Martínez-GarcíaJMJerónimo Martínez-García
Open Access
Abstract
Killer-cell immunoglobulin-like receptors (KIR) are expressed by natural killer (NK) and effector T cells. Although KIR+ T cells accumulate in oncologic patients, their role in cancer immune response remains elusive. This study explored the role of KIR+CD8+ T cells in cancer immunosurveillance by analyzing their frequency at diagnosis in the blood of 249 patients (80 melanomas, 80 bladder cancers, and 89 ovarian cancers), their relationship with overall survival (OS) of patients, and their gene expression profiles. KIR2DL1+ CD8+ T cells expanded in the presence of HLA-C2-ligands in patients who survived, but it did not in patients who died. In contrast, presence of HLA-C1-ligands was associated with dose-dependent expansions of KIR2DL2/S2+ CD8+ T cells and with shorter OS. KIR interactions with their specific ligands profoundly impacted CD8+ T cell expression profiles, involving multiple signaling pathways, effector functions, the secretome, and consequently, the cellular microenvironment, which could impact their cancer immunosurveillance capacities. KIR2DL1/S1+ CD8+ T cells showed a gene expression signature related to efficient tumor immunosurveillance, whereas KIR2DL2/L3/S2+CD8+ T cells showed transcriptomic profiles related to suppressive anti-tumor responses. These results could be the basis for the discovery of new therapeutic targets so that the outcome of patients with cancer can be improved.Keywords
Funding Information
- Instituto de Salud Carlos III (PI1302297)
- Fundación Mutua Madrileña (AP74392010)
- Fundación Séneca (20812-PI-18)
- Asociación Pablo Ugarte (APU) ((no number))
This publication has 54 references indexed in Scilit:
- NF-κB in immunobiologyCell Research, 2011
- The tortoise and the hare: slowly evolving T‐cell responses take hastily evolving KIRImmunology, 2010
- TNFR2-Deficient Memory CD8 T Cells Provide Superior Protection against Tumor Cell GrowthThe Journal of Immunology, 2009
- CD44 mobilization in allogeneic dendritic cell–T cell immunological synapse plays a key role in T cell activationJournal of Leukocyte Biology, 2008
- Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in diseaseClinical and Experimental Immunology, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- Natural Killer Receptors on CD8 T Cells and Natural Killer Cells from Different HLA-C Phenotypes in Melanoma PatientsClinical Cancer Research, 2006
- NKG2D Ligation without T Cell Receptor Engagement Triggers Both Cytotoxicity and Cytokine Production in Dendritic Epidermal T CellsJournal of Investigative Dermatology, 2006
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- REGULATION OF IMMUNE RESPONSES THROUGH INHIBITORY RECEPTORSAnnual Review of Immunology, 1999